Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30


A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.

Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM.

Oncotarget. 2017 May 16;8(20):32918-32929. doi: 10.18632/oncotarget.16464.


Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.


Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.


Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.

PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.



Hunsberger S, Rubinstein L, Boerner SA, LoRusso P.

J Natl Cancer Inst. 2013 Jul 3;105(13):993-4. doi: 10.1093/jnci/djt126. Epub 2013 May 30. No abstract available.


Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.

Gupta S, Hunsberger S, Boerner SA, Rubinstein L, Royds R, Ivy P, LoRusso P.

J Natl Cancer Inst. 2012 Dec 19;104(24):1860-6. doi: 10.1093/jnci/djs439. Epub 2012 Nov 19.


Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop.

LoRusso PM, Canetta R, Wagner JA, Balogh EP, Nass SJ, Boerner SA, Hohneker J.

Clin Cancer Res. 2012 Nov 15;18(22):6101-9. doi: 10.1158/1078-0432.CCR-12-2455. Epub 2012 Oct 12.


Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?

Lorusso PM, Boerner SA, Hunsberger S.

J Clin Oncol. 2011 Aug 1;29(22):2952-5. doi: 10.1200/JCO.2011.36.1311. Epub 2011 Jun 27. No abstract available.


Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?

LoRusso PM, Anderson AB, Boerner SA, Averbuch SD.

Clin Cancer Res. 2010 Dec 15;16(24):5956-62. doi: 10.1158/1078-0432.CCR-10-1279. Review.


Translating clinical trials into meaningful outcomes.

LoRusso PM, Schnipper LE, Stewart DJ, Boerner SA, Averbuch SD, Wolf W.

Clin Cancer Res. 2010 Dec 15;16(24):5951-5. doi: 10.1158/1078-0432.CCR-10-2632. Review.


The role of phosphoinositide 3-kinase in breast cancer: an overview.

LoRusso PM, Boerner SA.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S56-8. doi: 10.3816/CBC.2010.s.012. Review. No abstract available.


A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM.

Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14.


An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.

LoRusso PM, Boerner SA, Seymour L.

Clin Cancer Res. 2010 Mar 15;16(6):1710-8. doi: 10.1158/1078-0432.CCR-09-1993. Epub 2010 Mar 9. Review.


A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.

Burris HA 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, Ho PT, Boerner SA, Lorusso P.

Invest New Drugs. 2011 Jun;29(3):467-72. doi: 10.1007/s10637-009-9374-x. Epub 2010 Jan 13.


Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Eder JP, Vande Woude GF, Boerner SA, LoRusso PM.

Clin Cancer Res. 2009 Apr 1;15(7):2207-14. doi: 10.1158/1078-0432.CCR-08-1306. Epub 2009 Mar 24. Review.


A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.

Chianese-Bullock KA, Irvin WP Jr, Petroni GR, Murphy C, Smolkin M, Olson WC, Coleman E, Boerner SA, Nail CJ, Neese PY, Yuan A, Hogan KT, Slingluff CL Jr.

J Immunother. 2008 May;31(4):420-30. doi: 10.1097/CJI.0b013e31816dad10.


Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.

LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA, Wheeler C.

Invest New Drugs. 2008 Apr;26(2):159-67. doi: 10.1007/s10637-008-9112-9. Epub 2008 Jan 25.


Non-rash skin toxicities associated with novel targeted therapies.

Lacouture ME, Boerner SA, Lorusso PM.

Clin Lung Cancer. 2006 Dec;8 Suppl 1:S36-42. Review.


Clinical experience of MEK inhibitors in cancer therapy.

Wang D, Boerner SA, Winkler JD, LoRusso PM.

Biochim Biophys Acta. 2007 Aug;1773(8):1248-55. Epub 2006 Nov 16. Review.


Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.

Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW, Neese PY, Merrill P, Petroni GR, Slingluff CL Jr.

J Immunother. 2005 Jul-Aug;28(4):412-9.


PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation.

Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB, Marshall MS, Weber MJ, Parsons JT, Catling AD.

J Cell Biol. 2003 Jul 21;162(2):281-91.


Integrin connections map: to infinity and beyond.

Martin KH, Slack JK, Boerner SA, Martin CC, Parsons JT.

Science. 2002 May 31;296(5573):1652-3. Review.


Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells.

Kottke TJ, Blajeski AL, Meng XW, Svingen PA, Ruchaud S, Mesner PW Jr, Boerner SA, Samejima K, Henriquez NV, Chilcote TJ, Lord J, Salmon M, Earnshaw WC, Kaufmann SH.

J Biol Chem. 2002 Jan 4;277(1):804-15. Epub 2001 Oct 24.


Effect of P-glycoprotein on flavopiridol sensitivity.

Boerner SA, Tourne ME, Kaufmann SH, Bible KC.

Br J Cancer. 2001 May 18;84(10):1391-6.


The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH.

Cancer Res. 2001 Jan 15;61(2):739-48.


Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity.

Budihardjo II, Boerner SA, Eckdahl S, Svingen PA, Rios R, Ames MM, Kaufmann SH.

Mol Pharmacol. 2000 Mar;57(3):529-38.


Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.

Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt D Jr, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB, Kaufmann SH.

Clin Cancer Res. 2000 Feb;6(2):661-70.


Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent.

Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM.

Biochem Pharmacol. 1999 Sep 15;58(6):1057-66.


A one-step method for protein estimation in biological samples: nitration of tyrosine in nitric acid.

Bible KC, Boerner SA, Kaufmann SH.

Anal Biochem. 1999 Feb 1;267(1):217-21.


Supplemental Content

Loading ...
Support Center